Reference of 22013-33-8, Research speed reading in 2021. The prevalence of solvent effects has motivated developing quantitative kinetic, and theoretical assessments of solvent structures and their interactions with reaction intermediates. In a document type is Article, and a compound is mentioned, 22013-33-8, Name is 2,3-Dihydrobenzo[b][1,4]dioxin-6-amine, introducing its new discovery.
The inhibition of human glutaminyl cyclase (hQC) has come into focus as a new potential approach for the treatment of Alzheimer’s disease. The hallmark of this principle is the prevention of the formation of Abeta 3,11(pE)-40,42, as these Abeta-species were shown to be of elevated neurotoxicity and likely to act as a seeding core leading to an accelerated formation of Abeta-oligomers and fibrils. Starting from 1-(3-(1H-imidazol-1- yl)propyl)-3-(3,4-dimethoxyphenyl)thiourea, bioisosteric replacements led to the development of new classes of inhibitors. The optimization of the metal-binding group was achieved by homology modeling and afforded a first insight into the probable binding mode of the inhibitors in the hQC active site. The efficacy assessment of the hQC inhibitors was performed in cell culture, directly monitoring the inhibition of Abeta3,11(pE)-40,42 formation. 2009 American Chemical Society.
I am very proud of our efforts over the past few months and hope to 22013-33-8 help many people in the next few years. Reference of 22013-33-8